ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Sunday, November 13, 2016

9:00AM-11:00AM
Abstract Number: 684
Subchondral Bone Sclerosis on Computed Tomography – Does It Have Any Value in the Diagnosis of Inflammatory Sacroiliitis or Is It a Non-Specific Finding?
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment
9:00AM-11:00AM
Abstract Number: 521
Subcutaneous Adipose Tissue from Rheumatoid Arthritis Patients Is Characterized By an Abundance of Macrophages That Are Associated with Autoantibodies, Systemic Inflammation, and Immunomodulation
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis
9:00AM-11:00AM
Abstract Number: 175
Suppressor of Cytokine Function One (SOCS1) Is Elevated in Non-Classical Monocytes and Correlates with Disease Activity in Systemic Lupus Erythematosus Patients
Innate Immunity and Rheumatic Disease - Poster I
9:00AM-11:00AM
Abstract Number: 828
Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I
9:00AM-11:00AM
Abstract Number: 604
Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
9:00AM-11:00AM
Abstract Number: 626
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
9:00AM-11:00AM
Abstract Number: 639
Switching to Biosimilars in Rheumatology: Evidence-Based Practice
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I
9:00AM-11:00AM
Abstract Number: 676
Syndesmophytes in the Thoracic Spine in Ankylosing Spondylitis As Detected By Computed Tomography and Association with Lumbar Radiographic Involvement
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment
9:00AM-11:00AM
Abstract Number: 543
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis
9:00AM-11:00AM
Abstract Number: 573
Synovial Fibroblast-Neutrophil Interactions Promote Pathogenic Adaptive Immunity in Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I
9:00AM-11:00AM
Abstract Number: 587
Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I
9:00AM-11:00AM
Abstract Number: 153
Synovial Immunophenotype and Ultrasonography: A Contemporaneous Study of Different Compartments of the Knee Joint
Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies
9:00AM-11:00AM
Abstract Number: 134
Synovitis Assessed By the German 7-Joint Ultrasound Score (US7S) Is Associated with the Reversible Activity-Related Component of Physical Disability in Patients with Rheumatoid Arthritis 
Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies
9:00AM-11:00AM
Abstract Number: 157
Synovitis of Sternoclavicular and Peripheral Joints Can be Detected By Ultrasound in Patients with SAPHO Syndrome
Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies
9:00AM-11:00AM
Abstract Number: 121
Systemic Lupus Erythematosus (SLE) Is a Salient Cause of Premature Mortality in the United States: A Sex-Based Exploration
Healthcare Disparities in Rheumatology - Poster I
  • «Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 70
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology